Vir Biotechnology, Inc. Common Stock VIR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:45:07.958Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:32:31.923293255Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:45:07.269949+00:00
Vir Biotechnology, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 14.47 | 89.4% | 13.4% | 12.15 | 70.3% | 8.4% |
| 30Δ | 14.20 | 92.3% | 11.9% | 12.34 | 71.2% | 7.5% |
| 35Δ | 13.94 | 93.6% | 10.4% | 12.53 | 72.2% | 6.7% |
| 40Δ | 13.67 | 89.5% | 8.9% | 12.72 | 73.1% | 5.8% |
| 45Δ | 13.41 | 85.4% | 7.4% | 12.91 | 74.1% | 5.0% |
| 50Δ | 13.15 | 81.4% | 5.8% | 13.19 | 83.7% | 4.6% |
| 55Δ | 12.94 | 77.1% | 4.7% | 13.55 | 101.0% | 4.6% |
| 60Δ | 12.79 | 72.4% | 4.1% | 13.91 | 118.3% | 4.6% |
| 65Δ | 12.65 | 67.7% | 3.4% | 14.17 | 116.2% | 4.0% |
| 70Δ | 12.50 | 63.0% | 2.8% | 14.39 | 108.1% | 3.2% |
| 75Δ | 12.35 | 58.4% | 2.1% | 14.61 | 100.0% | 2.4% |
| 80Δ | 12.21 | 53.7% | 1.5% | 14.83 | 91.9% | 1.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 14.47
- IV
- 89.4%
- B/E move
- 13.4%
- Pseudo strike
- 12.15
- IV
- 70.3%
- B/E move
- 8.4%
30Δ
- Pseudo strike
- 14.20
- IV
- 92.3%
- B/E move
- 11.9%
- Pseudo strike
- 12.34
- IV
- 71.2%
- B/E move
- 7.5%
35Δ
- Pseudo strike
- 13.94
- IV
- 93.6%
- B/E move
- 10.4%
- Pseudo strike
- 12.53
- IV
- 72.2%
- B/E move
- 6.7%
40Δ
- Pseudo strike
- 13.67
- IV
- 89.5%
- B/E move
- 8.9%
- Pseudo strike
- 12.72
- IV
- 73.1%
- B/E move
- 5.8%
45Δ
- Pseudo strike
- 13.41
- IV
- 85.4%
- B/E move
- 7.4%
- Pseudo strike
- 12.91
- IV
- 74.1%
- B/E move
- 5.0%
50Δ
- Pseudo strike
- 13.15
- IV
- 81.4%
- B/E move
- 5.8%
- Pseudo strike
- 13.19
- IV
- 83.7%
- B/E move
- 4.6%
55Δ
- Pseudo strike
- 12.94
- IV
- 77.1%
- B/E move
- 4.7%
- Pseudo strike
- 13.55
- IV
- 101.0%
- B/E move
- 4.6%
60Δ
- Pseudo strike
- 12.79
- IV
- 72.4%
- B/E move
- 4.1%
- Pseudo strike
- 13.91
- IV
- 118.3%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 12.65
- IV
- 67.7%
- B/E move
- 3.4%
- Pseudo strike
- 14.17
- IV
- 116.2%
- B/E move
- 4.0%
70Δ
- Pseudo strike
- 12.50
- IV
- 63.0%
- B/E move
- 2.8%
- Pseudo strike
- 14.39
- IV
- 108.1%
- B/E move
- 3.2%
75Δ
- Pseudo strike
- 12.35
- IV
- 58.4%
- B/E move
- 2.1%
- Pseudo strike
- 14.61
- IV
- 100.0%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 12.21
- IV
- 53.7%
- B/E move
- 1.5%
- Pseudo strike
- 14.83
- IV
- 91.9%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 105.32% | |
| 90.73% | |
| 79.44% | |
| 88.73% | |
| 93.19% | |
| 97.11% | |
| 97.65% | |
| 86.38% | |
| 76.45% | |
| 85.97% |
Biotechnology
VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered…
More →VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is…
More →VOR
Description unavailable
More →VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
More →VRTX
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
More →VSTM
Description unavailable
More →